gip/glp-1 agonist Potential Use of GLP-1 and Receptor Agonists for Respiratory Disorders: Where Are We at? Upcoming wave of hormone-based therapies
Description
[DOI] [PMC free article] [PubMed] [Google Scholar] 36.Li X., Liu Y., Zheng Y., Wang P., Zhang Y
N Engl J Med 360(2):129139
A higher dose of liraglutide, up to 3 mg daily (Saxenda), has been approved by the US FDA for weight management in certain obese or overweight individuals
Problems can occur if severe nausea, vomiting, or diarrhea cause dehydration
Control mice with weight loss matching that of mice receiving 1 mg/kg liraglutide were not protected from atherosclerosis, suggesting that liraglutide has weight lossindependent anti-atherogenic effects
